AR and prostate adenocarcinoma: While primary NEPC is treated with platinum, taxol, and etoposide-based chemotherapeutics, patients with advanced PRAD (i.e., high-grade tumors ineligible for prostatectomy) are treated with AR-targeting agents with or without concurrent radiotherapy.